Polar Capital Funds PLC - Biotechnology Fund S IncRegister to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 36.7 | 5.9 | 4.9 | 10.0 | 1.0 | |
+/-Cat | 10.8 | 14.9 | 12.7 | 11.3 | 4.9 | |
+/-B’mrk | 3.8 | 5.6 | 2.4 | 2.7 | -5.4 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 08/05/2024 | USD 47.03 | |
Day Change | -0.60% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | IE00BF23BV98 | |
Fund Size (Mil) 08/05/2024 | USD 1699.61 | |
Share Class Size (Mil) 08/05/2024 | USD 14.87 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 31/12/2023 | 0.87% |
Investment Objective: Polar Capital Funds PLC - Biotechnology Fund S Inc |
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
David Pinniger 31/10/2013 | ||
Gareth Powell 31/10/2013 | ||
Inception Date 31/10/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Polar Capital Funds PLC - Biotechnology Fund S Inc | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Regeneron Pharmaceuticals Inc | Healthcare | 6.38 |
Amgen Inc | Healthcare | 5.50 |
argenx SE | Healthcare | 4.92 |
Blueprint Medicines Corp | Healthcare | 4.33 |
Zealand Pharma A/S | Healthcare | 4.09 |
Increase Decrease New since last portfolio | ||
Polar Capital Funds PLC - Biotechnology Fund S Inc |